One in six people in the UK has already received care from a clinician using Semble’s platform, without most of them ever knowing the software existed. That kind of quiet infrastructure scale, 10 million patients across 1,700 healthcare businesses, is exactly what convinced a new set of European growth investors that the company’s next move is worth backing.
London-based Semble has secured a £30 million Series C led by Paris-headquartered European growth investor Revaia, with participation from new investor Partech and returning backers Mercia Ventures and Octopus Ventures. The round brings Semble’s total funding to approximately £57 million, nearly doubling its capitalisation since the £11.5 million Series B it closed in October 2024.
What Semble does
Founded in 2016 by Christoph Lippuner and Mikael Landau – both second-time founders who previously built and exited a startup together – Semble began life as Heydoc before rebranding. Lippuner previously spent 11 years as an Executive Director at J.P. Morgan and co-founded Orogo before turning to healthcare technology. The company is headquartered in London with offices in Paris.
The problem Semble targets is structural. Private outpatient healthcare – clinics, specialist practices, hospital groups – typically runs on fragmented software: one system for scheduling, another for billing, a third for clinical records, and often none that talk to each other. The British Medical Association has estimated that doctors in England lose 13.5 million working hours a year to inadequate IT systems alone. Semble consolidates these functions into a single platform covering scheduling, billing, clinical records, reporting, prescriptions, and patient communications, and integrates with more than 1,200 external tools including diagnostics, labs, and CRM systems.
The company now serves 1,700 healthcare businesses across 80 specialities, used daily by 16,000 professionals. Customers include Nuffield Health, Welbeck, Midland Health, London Doctors Clinic, Modality, and ProblemShared. Headcount has grown by more than 50% since December 2024. Semble was named by TIME as one of the World’s Top HealthTech Companies for 2025.
Why now
The timing reflects a structural shift in how healthcare is financed in the UK. Private medical insurance uptake and self-pay care models are growing rapidly as NHS waiting lists remain stubbornly long, pushing more patients and more revenue into the private outpatient sector. Semble sits directly in the path of that shift, providing the operating infrastructure for providers who need to scale quickly without rebuilding their tech stacks. France represents Semble’s first international market, where it has already demonstrated regulatory maturity in less than a year – a credibility signal that makes the European expansion thesis credible rather than aspirational.
“For years, the industry has tried to address complex systemic issues through disconnected point solutions, but fragmented technology often adds operational complexity for healthcare providers and creates an interrupted experience for patients. What healthcare organisations need is intelligent orchestration across the entire care journey. The practices and groups that win over the next decade will be the ones that deliver the best patient experience end-to-end.” — Christoph Lippuner, CEO and Co-founder.
“Semble is building the system of action for modern healthcare — a platform with genuine clinical depth, real scale and the trust of healthcare providers across the UK and France. The European healthcare market is being reshaped — by technology, by demand and by shifting patient expectations — and Semble is exceptionally well positioned to lead it.” — Morgan Kessous, Partner, Revaia.
The investors
Revaia, founded in 2018 by Alice Albizzati and Elina Berrebi and managing over €600 million in assets, focuses on European growth-stage technology companies. Its portfolio includes Aircall (cloud telephony), Algolia (search and discovery APIs), Mews (hotel property management), Hublo (healthcare staff management), and Deepki (ESG data intelligence). Partech, which co-invests alongside Revaia here, is a global firm managing over $3 billion with offices across Paris, Berlin, Dakar, and San Francisco. Returning investor Mercia Ventures led Semble’s Series B in October 2024, and Octopus Ventures, which has backed companies including Perci Health and DRIFT Energy, also returns.
The competitive landscape
Semble’s most direct UK competitor is Carebit (formerly known as WriteUpp), a cloud-based practice management platform focused on allied health and therapy practices, which has raised smaller pre-Series A amounts. In the US, athenahealth, part of Ellkay and Practice Fusion serve similar EHR and practice management functions for outpatient providers, though both are built primarily for the American insurance billing model rather than the UK’s private pay and PMI structure. Internationally, Tuum, the Estonian core banking-style infrastructure platform for healthcare, has taken a similar ‘replace the legacy layer’ approach in adjacent markets. Semble’s differentiation is its depth of integration – 1,200 connected tools – and its regulatory track record across two different European healthcare systems.
Market context
According to Grand View Research, the global healthcare IT market was valued at $866.48 billion in 2025 and is projected to reach $2.86 trillion by 2033, growing at a CAGR of 16.2%. The UK private healthcare market specifically was valued at $13.75 billion in 2024 and is projected to reach $18.56 billion by 2033, driven by rising self-pay patients and PMI expansion.
The deeper question Semble’s raise forces the market to answer is whether a single connected platform for private outpatient care can become as structurally indispensable in Europe as the hospital EHR incumbents became in the US and whether the fragmented European market will let it happen before the American giants decide to cross the Atlantic.
